What is the recommended management of herpes zoster ophthalmicus?

Management of Herpes Zoster Ophthalmicus

Start oral valacyclovir 1000 mg three times daily for 7 days immediately upon diagnosis, ideally within 72 hours of rash onset, and refer urgently to ophthalmology for slit-lamp examination to assess for ocular complications. 1, 2

Immediate Systemic Antiviral Therapy

Oral antiviral therapy is the cornerstone of treatment and must be initiated as soon as possible:

• Valacyclovir 1000 mg three times daily for 7 days is the preferred first-line regimen in immunocompetent adults due to superior dosing convenience and bioavailability 1, 2
• Alternative regimens include acyclovir 800 mg five times daily for 7 days or famciclovir 500 mg three times daily for 7 days 1, 2
• Treatment initiated within 72 hours of rash onset significantly reduces ocular complications from 50-71% down to 29% and decreases post-herpetic neuralgia from typical rates to only 13% 3
• A 7-day course is sufficient; extending to 14 days provides no additional benefit in immunocompetent patients 3

Dose adjustments are critical in renal impairment to avoid nephrotoxicity—reduce valacyclovir and acyclovir doses according to creatinine clearance 1, 2

Adjunctive Topical Management

Apply topical antibiotics (such as erythromycin or bacitracin ointment) to vesicular skin lesions to prevent secondary bacterial infection, which can lead to severe cicatricial ectropion and chronic lid malposition 1, 2

Topical antivirals alone are ineffective for varicella-zoster virus conjunctivitis and should not be used as monotherapy; they may only be added (ganciclovir 0.15% gel or trifluridine 1% solution) in unresponsive patients already on adequate systemic therapy 1, 2

Critical Corticosteroid Precautions

Never use topical corticosteroids during active epithelial viral infection—they potentiate viral replication and worsen disease 1, 2

Corticosteroids may only be considered after epithelial healing for inflammatory complications such as stromal keratitis, uveitis, or subepithelial infiltrates causing vision loss, and only under direct ophthalmologist supervision 1, 2

When corticosteroids are indicated:

• Use agents with poor ocular penetration (fluorometholone or loteprednol) to minimize risk of elevated intraocular pressure and cataract 1, 2
• Employ the minimum effective dose with slow taper 1, 2
• Monitor intraocular pressure regularly and perform dilated fundus examination to screen for glaucoma and cataract 1, 2

Urgent Ophthalmology Referral

All patients with herpes zoster ophthalmicus require ophthalmology consultation to assess for ocular involvement 4, 5

Perform slit-lamp biomicroscopy with fluorescein staining to detect:

• Pseudodendritic keratitis (non-excavated lesions distinct from HSV dendrites) 2
• Punctate epithelial keratitis 2
• Stromal keratitis and corneal vascularization 1
• Anterior uveitis and sectoral iris atrophy 1, 2
• Elevated intraocular pressure (secondary glaucoma) 1, 2

Conduct dilated fundus examination if posterior segment involvement (retinitis, acute retinal necrosis) is suspected 2, 6

Follow-Up Protocol

Schedule follow-up within 1 week of treatment initiation including:

• Interval history focusing on pain, visual changes, and new ocular symptoms 1, 2
• Visual acuity measurement 1, 2
• Slit-lamp biomicroscopy to detect early complications 1, 2

Monitor for late sequelae including dry eye, corneal anesthesia with neurotrophic keratitis, and chronic ocular inflammation requiring ongoing ophthalmologic care 1, 2

Special Populations

Immunocompromised patients require more aggressive therapy:

• Consider higher doses or prolonged treatment duration based on clinical response 1
• Complicated cases (disseminated disease, severe ocular involvement) require intravenous acyclovir 2
• In severe disseminated VZV, consider temporarily discontinuing immunosuppressive therapy until skin vesicles resolve and antiviral therapy is established 2

Prevention

The recombinant zoster vaccine (Shingrix) is strongly recommended for all immunocompetent patients aged 50 years and older, with 96% efficacy in preventing herpes zoster and its complications including HZO 1, 7

Vaccination is also recommended for immunocompromised patients aged 19 years and older 8, 7

Common Pitfalls to Avoid

• Delaying antiviral therapy beyond 72 hours significantly reduces effectiveness in preventing ocular complications 4, 6, 3
• Using topical corticosteroids without ophthalmology supervision risks worsening infection and causing corneal perforation 1, 2
• Failing to adjust antiviral doses in renal impairment can cause nephrotoxicity 1, 2
• Not recognizing Hutchinson's sign (vesicles on the tip or side of the nose) which indicates nasociliary nerve involvement and predicts higher risk of ocular complications 4
• Inadequate long-term follow-up misses late complications such as neurotrophic keratitis and chronic uveitis 1, 2